What is Pentetate Zinc Trisodium Zn DTPA
Pentetate zinc trisodium Zn DTPA is a radiomitigation chelating agent indicated for the treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium.
Treatment with Zn-DTPA increases the rate of elimination of these radioactive contaminants.
When the sources of radiation contamination are multiple or unknown, other therapies (such as potassium iodide, insoluble Prussian blue, or sodium alginate) can be used in combination with Zn-DTPA. Chelation treatment should begin immediately, with contamination verified as soon as possible.
If treatment cannot be started right away, patients should begin therapy soon as it becomes available, as treatment is still effective even after time has elapsed since exposure.
Zn-DTPA should not be administered simultaneously with Ca-DTPA due to the duplicative nature of the treatments. If both products are available, Ca-DTPA should be given as the first dose.
If additional treatment is needed, treatment should be switched to Zn-DTPA, if Zn-DTPA is available.
This treatment sequence is recommended because Ca-DTPA is more effective than Zn-DTPA during the first 24 hours after internal contamination.
After the initial 24 hours, Zn-DTPA and Ca-DTPA are similarly effective, but Ca-DTPA causes more mineral loss.
The Zn-DTPA product labeling contains Black Box Warnings (BBW) regarding the potential for depletion of trace minerals and the potential for asthma exacerbation with inhaled administration
- radiation exposure
For treatment of individuals with known or suspected internal contamination with radiation exposure to plutonium, americium, or curium to increase the rates of elimination
- pelvic pain
- CBC with differential
- serum creatinine/BUN
- serum electrolytes
- bone marrow suppression
- electrolyte imbalance
- pulmonary disease
- radiation exposure
- renal failure
- renal impairment
There are no drug interactions associated with Pentetate Zinc Trisodium, Zn-DTPA products.